New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients ...
Nasdaq

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Spokane's Deaconess Hospital starts program to combat drug withdrawal with long-lasting medication

A pilot program from MultiCare Deaconess Hospital now provides long lasting opioid withdrawal medication. The injectable buprenorphine will provide a much more stable basis for patients to ...
Medscape

High-Dose Buprenorphine for OUD With High Fentanyl Use?

For adults with high-risk opioid use disorder (OUD), both 100-mg or 300-mg monthly maintenance injections of extended-release buprenorphine improved opioid abstinence, but the higher dose seemed to ...
Morningstar

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with ...